Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 1257 results for pathway

  1. Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)

    Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    11 May 2022
    View recommendations

    Sections for TA788

  2. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA394

  3. Fruquintinib for previously treated metastatic colorectal cancer (TA1079)

    Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    23 July 2025
    View recommendations

    Sections for TA1079

  4. Adults' uptake of and engagement with interventions for social anxiety disorder:- What methods are effective in improving uptake of and engagement with interventions for adults with social anxiety disorder?

    uptake and engagement, including: - Development and evaluation of improved pathways into care, in collaboration with low users of...

    Research recommendation
    Published
    9 June 2015

  5. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    and may not be conclusive. Understanding and mapping changes in molecular pathways could predict outcome and inform individual treatment...

    Research recommendation
    Published
    4 August 2022

  6. Routine outcome measurement:- In people with a common mental health disorder, what is the clinical utility of routine outcome measurement and is it cost effective compared with standard care?

    Comes from guidance Common mental health problems: identification and pathways to care Number CG123 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  7. Generalized Anxiety Disorder scale (GAD-2) for people with suspected anxiety disorders:- In people with suspected anxiety disorders, what is the clinical utility of using the GAD-2 compared with routine case identification to accurately identify different anxiety disorders? Should an avoidance question be added to improve case identification?

    Comes from guidance Common mental health problems: identification and pathways to care Number CG123 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  8. Identifying health conditions:- What is the effectiveness and cost effectiveness of different ways of identifying age-related and other physical and mental health conditions, in people growing older with learning disabilities?What can mainstream and specialist health services do to facilitate:- early identification of health conditions in people with learning disabilities?- equal access to health services in people with learning disabilities?

    health checks, we did not find any evidence about different methods and pathways for identifying health conditions among people growing...

    Research recommendation
    Published
    29 November 2018

  9. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTG700)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.

    HealthTech guidance
    Last updated
    6 March 2024
    View recommendations

    Sections for HTG700

  10. Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)

    Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.

    HealthTech guidance
    Published
    5 February 2026
    View recommendations

    Sections for HTG769

  11. Methods research areas

    NICE priority methodological research areas.

  12. Interventional procedures programme manual (PMG28)

    This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual

  13. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

    Technology appraisal guidance
    Last updated
    26 October 2023
    View recommendations

    Sections for TA274

  14. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.

    Technology appraisal guidance
    Published
    15 December 2021
    View recommendations

    Sections for TA752

  15. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 February 2025

    Sections for TA1037